Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chappell, M. C.
Right arrow Articles by Ferrario, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chappell, M. C.
Right arrow Articles by Ferrario, C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 22-26
© 2001 European Renal Association-European Dialysis and Transplant Association

Pathways of angiotensin-(1–7) metabolism in the kidney

Mark C. Chappell, Alicia J. Allred and Carlos M. Ferrario

The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1032, USA

Angiotensin-(1–7) [Ang-(1–7)], which can be formed directly from angiotensin I (Ang I) bypassing the requisite production of Ang II, is a bioactive component of the renin–angiotensin system that may oppose the actions of Ang II. In contrast to the generation of Ang II, angiotensin-converting enzyme (ACE) hydrolyses Ang-(1–7) to inactive fragments. ACE inhibitors substantially augment circulating levels of Ang-(1–7) and increase the peptide's half-life. Thus, this enzymatic pathway constitutes a key regulatory point in the vasculature to balance the actions of Ang II, Ang-(1–7) and bradykinin. In contrast, the renal pathways for the metabolism of Ang-(1–7) appear quite distinct. Characterization of this pathway may shed new light on the potential actions of the peptide in the kidney, as well as the mechanisms of novel vasoactive peptidase therapies. We summarize recent experimental and clinical studies that begin to reveal novel pathways in the formation and degradation of Ang-(1–7) in the kidney.

Keywords: angiotensin-(1–7); angiotensin-converting enzyme; kidney; metabolism

Correspondence and offprint requests to: Mark C. Chappell, PhD, Hypertension and Vascular Disease Center, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27015, USA.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 pdiHome page
Y.-W. Fang and C.-H. Chang
SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS
Perit. Dial. Int., March 1, 2009; 29(2): 199 - 203.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A. Pignone, A. D. Rosso, K B. Brosnihan, F. Perfetto, R. Livi, G. Fiori, S. Guiducci, M. Cinelli, V. Rogai, A. Tempestini, et al.
Reduced circulating levels of angiotensin-(1 7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control
Ann Rheum Dis, October 1, 2007; 66(10): 1305 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Lucas, F. Carrera, C. Jorge, H. Boquinhas, and M. J. Pais
Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients
Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3202 - 3206.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Carrera, L. Oliveira, P. Maia, T. Mendes, and C. Ferreira
The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2846 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
K. D. Pendergrass, D. B. Averill, C. M. Ferrario, D. I. Diz, and M. C. Chappell
Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2.Lewis rat
Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1497 - F1506.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Brunkhorst, J. Bommer, J. Braun, M. Haag-Weber, C. Gill, J. Wagner, and T. Wagener
Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients
Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1224 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Stegbauer, V. Oberhauser, O. Vonend, and L. C. Rump
Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats
Cardiovasc Res, February 1, 2004; 61(2): 352 - 359.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
L. Ying, M. Flamant, S. Vandermeersch, J.-J. Boffa, C. Chatziantoniou, J.-C. Dussaule, and D. Chansel
Renal Effects of Omapatrilat and Captopril in Salt-Loaded, Nitric Oxide-Deficient Rats
Hypertension, November 1, 2003; 42(5): 937 - 944.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Fourtounas
Evidence-based or stock market-driven nephrology?
Nephrol. Dial. Transplant., April 1, 2002; 17(4): 690 - 691.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.